PA
ODT

Perceptive Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Perceptive Advisors’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$1.94M – 136
2018
Q3 		$1.94M Sell
100,000
-50,000
-33% -$1.02M 0.05% 85
2018
Q2 		$3.31M Hold
150,000
– – 0.09% 81
2018
Q1 		$3.18M Hold
150,000
– – 0.09% 87
2017
Q4 		$3.75M Buy
+150,000
New +$3.54M 0.12% 76

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors's ODT Position: Q4 2018 in Review

Perceptive Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2018, closing a stake of 100,000 shares — an estimated $1.94M sold.

Perceptive Advisors first reported a position in ODT in Q4 2017 and held it in 4 quarters. The position peaked at $3.75M in Q4 2017. 55 funds tracked by Wall St. Rank hold ODT as of Q4 2018.

  • Perceptive Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Perceptive Advisors sold 100,000 Odonate Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $1.94M.
  • Perceptive Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Perceptive Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $3.75M in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.